A 2-Part, Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against Factor XI, for the Treatment and Secondary Prevention of Venous Thromboembolism in Participants With Solid and Hematologic Cancers (ROXI-CAT-II)
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Enrollment
- 1,600
- Locations
- 17
- Primary Endpoint
- Severity of TEAEs
Study Overview
Brief Summary
This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2. The study is focused on participants with or without cancer who develop blood clots in certain veins (called Deep Vein Thrombosis [DVT]) that block blood flow (Part 1) or focused on participants with cancer who develop blood clots in certain veins (DVT) or the lungs (also called Pulmonary Embolism [PE]) (Part 2).
The aim of the study is to see how safe and effective the study drug is at treating and preventing further blood clots in participants with or without cancer (Part 1) or in participants with cancer (Part 2) compared with another treatment (apixaban).
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 at the time of screening and day 1 prior to first dose of study intervention
- •In Part 1 participants with cancer and Part 2 participants: Histologically confirmed diagnosis of malignant solid or select hematologic tumor (other than basal-cell or squamous-cell carcinoma of the skin alone) as described in the protocol
- •Part 1 additional criteria:
- •Has newly diagnosed symptomatic lower extremity DVT or incidentally-detected proximal lower extremity DVT (eg, popliteal or femoral) within 5 days (120 hours) of randomization (with imaging confirmation)
- •Anticoagulation therapy with a therapeutic dose of a Direct Oral Anticoagulant (DOAC) for at least 3 months is indicated for the newly diagnosed proximal lower extremity DVT
- •Part 2 additional criteria:
- •Newly diagnosed VTE within 5 days (120 hours) of randomization (with imaging confirmation) as described in the protocol
- •Anticoagulation therapy with a therapeutic dose of a DOAC for at least 6 months is indicated for newly diagnosed VTE
Exclusion Criteria
- •Is at high risk of intracranial bleeding in the opinion of the investigator
- •Known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy)
- •Contraindication to anticoagulation in the opinion of the investigator
- •Life expectancy of < 6 months
- •Part 1 participants with cancer and Part 2 additional exclusion criteria:
- •Has acute leukemia or myelodysplastic syndrome
- •Has primary brain tumor
- •Has brain metastases as described in the protocol
- •Part 1 additional exclusion criteria:
- •Has a symptomatic PE
- •Has an asymptomatic (incidentally-diagnosed) PE in a segmental or larger pulmonary artery
- •Part 2 additional exclusion criteria: PE leading to hemodynamic instability as described in the protocol
- •Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
Arms & Interventions
REGN7508
Intervention: REGN7508 (Drug)
Apixaban
Intervention: Apixaban (Drug)
Outcomes
Primary Outcomes
Severity of TEAEs
Time Frame: Approximately 6 months
Part 1
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Approximately 6 months
Part 1
Time-to-first event of centrally adjudicated recurrent VTE [DVT (symptomatic or asymptomatic [proximal] or Non-fatal PE (symptomatic or asymptomatic [in a segmental or larger pulmonary artery] )or VTE-related death)]
Time Frame: Up to approximately 3.5 years
Part 2
Time-to-first event of centrally adjudicated International Society of Thrombosis and Hemostasis (ISTH)-defined major bleeding or Clinically Relevant Non-Major (CRNM) bleeding
Time Frame: Up to approximately 3.5 years
Part 2
Secondary Outcomes
- Percent inhibition of Factor XI functional Coagulant activity (FXI:C)(Approximately 3 months)
- Fold change from baseline in activated Partial Thromboplastin Time (aPTT)(Approximately 3 months)
- Functional REGN7508 concentration(Approximately 3 months)
- Factor XI (FXI) concentration(Approximately 3 months)
- Occurrence of Anti-Drug Antibody (ADA) to REGN7508(Up to approximately 3.5 years)
- Magnitude of ADA to REGN7508(Up to approximately 3.5 years)
- Time-to-first centrally adjudicated event of DVT (symptomatic or asymptomatic [proximal])(Up to approximately 3.5 years)
- Time-to-first centrally adjudicated event of Non-fatal PE (symptomatic or asymptomatic [in a segmental or larger pulmonary artery])(Up to approximately 3.5 years)
- Time-to-first centrally adjudicated event of VTE-related death(Up to approximately 3.5 years)
- Time-to-first event of centrally adjudicated venous thromboembolic events other than DVT and PE(Up to approximately 3.5 years)
- Time-to-first event of centrally adjudicated Arterial Thromboembolism (ATE)(Up to approximately 3.5 years)
- Time-to-first event of centrally adjudicated recurrent VTE and bleeding events [DVT (symptomatic or asymptomatic [proximal] or Non-fatal PE (symptomatic or asymptomatic) or VTE-related death) or bleeding (ISTH-defined major bleeding or CRNM bleeding)](Up to approximately 3.5 years)
- Occurrence of TEAEs(Up to approximately 3.5 years)
- Severity of TEAEs(Up to 3.5 approximately years)